Vimarsana
Biggest News Aggregation in the World

Page 26 - Celularity Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Celularity Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Celularity Inc Today - Breaking & Trending Today

Pre-market Movers: EBET, AFRM, CELU, FIGS, LLAP. - Vimarsana News

Pre-market Movers: EBET, AFRM, CELU, FIGS, LLAP.

OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.30 A.M. ET).In the GreenEsports Technologies, Inc. (EBET) is up over 33% at $3.68 Affirm

Critical Review: Enochian Biosciences (NASDAQ:ENOB) and Celularity (NASDAQ:CELU) - Vimarsana News

Critical Review: Enochian Biosciences (NASDAQ:ENOB) and Celularity (NASDAQ:CELU)

Enochian Biosciences (NASDAQ:ENOB – Get Rating) and Celularity (NASDAQ:CELU – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk. Profitability This table compares Enochian Biosciences and Celularity’s net margins, […]

-$0.23 EPS Expected for Celularity Inc. (NASDAQ:CELU) This Quarter - Vimarsana News

-$0.23 EPS Expected for Celularity Inc. (NASDAQ:CELU) This Quarter

Equities research analysts expect Celularity Inc. (NASDAQ:CELU – Get Rating) to post earnings of ($0.23) per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Celularity’s earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.29). The company is scheduled to […]

Celularity (NASDAQ:CELU) Cut to "Hold" at Zacks Investment Research - Vimarsana News

Celularity (NASDAQ:CELU) Cut to "Hold" at Zacks Investment Research

Zacks Investment Research lowered shares of Celularity (NASDAQ:CELU – Get Rating) from a buy rating to a hold rating in a report published on Monday, Zacks.com reports. According to Zacks, “Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified […]

Celularity (NASDAQ:CELU) Shares Gap Down to $8.88 - Vimarsana News

Celularity (NASDAQ:CELU) Shares Gap Down to $8.88

Celularity Inc. (NASDAQ:CELU – Get Rating)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $8.88, but opened at $8.62. Celularity shares last traded at $8.69, with a volume of 234 shares changing hands. A number of research analysts recently commented on CELU shares. Zacks Investment Research downgraded […]